Irina Ridley - Neuropace Chief Secretary
| NPCE Stock | USD 8.98 0.70 7.23% |
Executive
Irina Ridley is Chief Secretary of Neuropace
| Age | 38 |
| Address | 455 North Bernardo Avenue, Mountain View, CA, United States, 94043 |
| Phone | 650 237 2700 |
| Web | https://www.neuropace.com |
Irina Ridley Latest Insider Activity
Tracking and analyzing the buying and selling activities of Irina Ridley against Neuropace stock is an integral part of due diligence when investing in Neuropace. Irina Ridley insider activity provides valuable insight into whether Neuropace is net buyers or sellers over its current business cycle. Note, Neuropace insiders must abide by specific rules, including filing SEC forms every time they buy or sell Neuropace'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Irina Ridley over three months ago Acquisition by Irina Ridley of 80000 shares of Neuropace subject to Rule 16b-3 | ||
Irina Ridley over a year ago Neuropace exotic insider transaction detected |
Neuropace Management Efficiency
The company has return on total asset (ROA) of (0.1474) % which means that it has lost $0.1474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1455) %, meaning that it created substantial loss on money invested by shareholders. Neuropace's management efficiency ratios could be used to measure how well Neuropace manages its routine affairs as well as how well it operates its assets and liabilities. As of November 15, 2024, Return On Tangible Assets is expected to decline to -0.32. In addition to that, Return On Capital Employed is expected to decline to -0.31. At present, Neuropace's Asset Turnover is projected to slightly decrease based on the last few years of reporting.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jon Shear | Nevro Corp | N/A | |
| Chris Calcaterra | Glaukos Corp | 64 | |
| James Chase | Anika Therapeutics | N/A | |
| Christofer Christoforou | Nevro Corp | 54 | |
| Ben Joseph | Anika Therapeutics | N/A | |
| Greg Siller | Nevro Corp | 43 | |
| Jonelle Burnham | CVRx Inc | 53 | |
| William George | Electromed | 75 | |
| David Caraway | Nevro Corp | 63 | |
| Steve Kachelmeyer | Iradimed Co | N/A | |
| Amy Yanta | Electromed | N/A | |
| Robert Thomson | Artivion | 54 | |
| MSc MD | CVRx Inc | N/A | |
| Robert JD | Paragon 28 | 57 | |
| Dan Yarbrough | Orthofix Medical | N/A | |
| Tonya SPHR | CVRx Inc | 52 | |
| David Lehman | Pulmonx Corp | 63 | |
| Michele Allegretto | Glaukos Corp | N/A | |
| Matthew Brinckman | Paragon 28 | N/A | |
| MD FACS | Glaukos Corp | N/A | |
| Frank Vizesi | Orthofix Medical | N/A | |
Management Performance
| Return On Equity | -2.15 | ||||
| Return On Asset | -0.15 |
Neuropace Leadership Team
Elected by the shareholders, the Neuropace's board of directors comprises two types of representatives: Neuropace inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neuropace. The board's role is to monitor Neuropace's management team and ensure that shareholders' interests are well served. Neuropace's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neuropace's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Irina Ridley, Chief Secretary | ||
| Chi Nguyen, VP Marketing | ||
| Kelley Nicholas, Vice Sales | ||
| Michael Favet, CEO Pres | ||
| Rebecca Kuhn, VP CFO | ||
| Mark Saxton, VP Sales | ||
| Leah Akin, Acting Counsel | ||
| Irene Thomas, Vice Resources | ||
| Martha Morrell, Chief Officer | ||
| Dylan John, Chief Development | ||
| Amy Treadwell, Vice Resources | ||
| Andre Marquette, Chief Officer | ||
| Joel Becker, President CEO |
Neuropace Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neuropace a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.15 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.37) % | ||||
| Operating Margin | (0.20) % | ||||
| Current Valuation | 288.2 M | ||||
| Shares Outstanding | 29.2 M | ||||
| Shares Owned By Insiders | 4.19 % | ||||
| Shares Owned By Institutions | 83.77 % | ||||
| Number Of Shares Shorted | 437.93 K | ||||
| Price To Book | 27.32 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neuropace is a strong investment it is important to analyze Neuropace's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuropace's future performance. For an informed investment choice regarding Neuropace Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Revenue Per Share 2.697 | Quarterly Revenue Growth 0.282 | Return On Assets (0.15) | Return On Equity (2.15) |
The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.